About Kalaris Therapeutics Inc
https://kalaristx.comKalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
CEO
Andrew Oxtoby
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-01-16 | Reverse | 1:23 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
SAMSARA BIOCAPITAL, LLC
Shares:11.45M
Value:$105.78M
TANG CAPITAL MANAGEMENT LLC
Shares:418.24K
Value:$3.86M
SIREN, L.L.C.
Shares:318.26K
Value:$2.94M
Summary
Showing Top 3 of 33
About Kalaris Therapeutics Inc
https://kalaristx.comKalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $12.74M ▲ | $-11.89M ▼ | 0% | $-0.64 ▼ | $-11.89M ▼ |
| Q2-2025 | $0 | $12.26M ▲ | $-11.35M ▼ | 0% | $-0.61 ▲ | $-11.35M ▼ |
| Q1-2025 | $0 | $10.35M ▼ | $-10.2M ▲ | 0% | $-2.52 ▲ | $-8.75M ▲ |
| Q3-2024 | $0 | $37.85M ▲ | $-38.08M ▼ | 0% | $-7.64 ▼ | $-37.27M ▼ |
| Q2-2024 | $0 | $4.19M | $-5.65M | 0% | $-1.13 | $-5.15M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $77M ▼ | $81.17M ▼ | $39.31M ▼ | $41.87M ▼ |
| Q2-2025 | $88.43M ▼ | $92.84M ▼ | $39.73M ▲ | $53.12M ▼ |
| Q1-2025 | $100.97M ▲ | $103.09M ▲ | $39.22M ▼ | $63.87M ▲ |
| Q3-2024 | $1.91M ▼ | $2.46M ▼ | $91.84M ▲ | $-89.38M ▼ |
| Q4-2023 | $3.17M | $3.33M | $48.35M | $-45.02M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.89M ▼ | $-11.33M ▲ | $-34.71M ▼ | $0 ▼ | $-46.04M ▼ | $-11.52M ▲ |
| Q2-2025 | $-11.35M ▼ | $-14.88M ▼ | $0 | $2.35M ▼ | $-12.54M ▼ | $-14.88M ▼ |
| Q1-2025 | $-10.2M ▼ | $-7.44M ▼ | $0 | $107.27M ▲ | $99.83M ▲ | $-7.44M ▼ |
| Q2-2024 | $-5.65M ▼ | $-3.97M ▲ | $0 | $4.98M ▼ | $1.01M ▼ | $-3.97M ▲ |
| Q1-2024 | $-3.41M | $-4.52M | $0 | $6.58M | $2.06M | $-4.52M |
CEO
Andrew Oxtoby
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-01-16 | Reverse | 1:23 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
SAMSARA BIOCAPITAL, LLC
Shares:11.45M
Value:$105.78M
TANG CAPITAL MANAGEMENT LLC
Shares:418.24K
Value:$3.86M
SIREN, L.L.C.
Shares:318.26K
Value:$2.94M
Summary
Showing Top 3 of 33